A Korean Company preoccupies the patents on Umbilical Cord Blood Stem Cell
Histostem Ltd. of South Korea acquired the patents of the original technologies on Umbilical Cord Blood in the US and EU.
A Korean biocompany has preoccupied the patents of the original technologies by which Mesenchymal Stem Cell can be isolated from Umbilical Cord Blood stem cell and cultured to be used in treating illnesses.
Histostem, a company specializing in cord blood stem cells, announced on February 2, 2010 that its patent has been registered with the USPTO which is a method of isolating and culturing ‘mesenchymal stem cell‘, a type of adult stem cells, from frozen umbilical cord blood.
The company has previously obtained a US patent which can isolate and culture ‘mesenchymal stem cell’ from fresh umbilical cord blood, and an EU patent entitled ‘Method of isolating and culturing ‘mesenchymal stem cell’ before or after freezing cord blood respectively.
By acquiring the EU patent, Histostem Ltd. will be able to dominate the market for the cord blood stem cell in the 27 EU countries including Britain, Germany and France for 20 years, said the company.
Also, in the US, according to the company, the treatment using the adult stem cell based on umbilical cord blood is only possible through the technology of Histostem.
The stem cell derived from umbilical cord blood, which is proved to be excellent in treating many diseases, is now the subject of active and competitive researches around the world.
Hoon Han, the representative of the company, said the separation and cultivation of stem cells from cord blood in the US and EU would cause the infringements on the Histostem’s patents, which means the use of stem cells isolated and cultured from umbilical cord blood is in the scope of the patent regardless of the stem cells are frozen or not.
Histostem reserved about 85,000 units of umbilical cord blood banks granted, which is the biggest in the world.